Whether a generic for the second-generation chronic myeloid leukemia treatment ‘Sprycel (dasatinib, BMS)’ will be introduced following generics for the first-generation ‘Gleevec (imatinib mesylate, Novartis)' is gaining attention.

If introduced, Sprycel’s generic is expected to greatly improve patient accessibility.

According to the industry on the 28th, Boryung Pharmaceutical is starting to develop a generic for Sprycel.

Since 2013 when the first generic Gleevec was introduced to the market, domestic pharmaceutical companies have attempted the development of a generic version of Sprycel. However, the companies were not able to progress due to patents, etc.